157 related articles for article (PubMed ID: 37963164)
1. A long-term retrospective cohort-based risk-benefit analysis of augmenting total cumulative I-131 activity to 37GBq in differentiated thyroid cancer patients with skeletal metastases.
Kanankulam Velliangiri S; Ballal S; Prasad Yadhav M; Tripathi M; Satapathy S; Bal C
PLoS One; 2023; 18(11):e0294343. PubMed ID: 37963164
[TBL] [Abstract][Full Text] [Related]
2. Improved Survival After Multimodal Approach with
Wu D; Gomes Lima CJ; Moreau SL; Kulkarni K; Zeymo A; Burman KD; Wartofsky L; Van Nostrand D
Thyroid; 2019 Jul; 29(7):971-978. PubMed ID: 31017051
[No Abstract] [Full Text] [Related]
3. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
4. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
[TBL] [Abstract][Full Text] [Related]
5. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up.
Qiu ZL; Shen CT; Sun ZK; Song HJ; Xi C; Zhang GQ; Wang Y; Luo QY
Front Endocrinol (Lausanne); 2020; 11():588024. PubMed ID: 33716950
[TBL] [Abstract][Full Text] [Related]
7. DEATH RELATED TO PULMONARY METASTASIS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER.
Leite AK; Kulcsar MA; de Godoi Cavalheiro B; de Mello ES; Alves VA; Cernea CR; Matos LL
Endocr Pract; 2017 Jan; 23(1):72-78. PubMed ID: 27749128
[TBL] [Abstract][Full Text] [Related]
8. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.
Lang BH; Wong KP; Cheung CY; Wan KY; Lo CY
Ann Surg Oncol; 2013 Apr; 20(4):1329-35. PubMed ID: 23104708
[TBL] [Abstract][Full Text] [Related]
10. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of radioiodine therapy for treating 20 patients with pulmonary metastases from differentiated thyroid cancer and a meta-analysis of the current literature.
Zhang X; Liu DS; Luan ZS; Zhang F; Liu XH; Zhou W; Zhong SF; Lai H
Clin Transl Oncol; 2018 Jul; 20(7):928-935. PubMed ID: 29119458
[TBL] [Abstract][Full Text] [Related]
12. Metastatic differentiated thyroid carcinoma: clinicopathological profile and outcome in an iodine deficient area.
Mishra A; Mishra SK; Agarwal A; Das BK; Agarwal G; Gambhir S
World J Surg; 2002 Feb; 26(2):153-7. PubMed ID: 11865341
[TBL] [Abstract][Full Text] [Related]
13. LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND BONE METASTASES.
Slook O; Levy S; Slutzky-Shraga I; Tsvetov G; Robenshtok E; Shimon I; Benbassat C; Hirsch D
Endocr Pract; 2019 May; 25(5):427-437. PubMed ID: 30657361
[No Abstract] [Full Text] [Related]
14. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
[No Abstract] [Full Text] [Related]
15. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.
Carhill AA; Litofsky DR; Ross DS; Jonklaas J; Cooper DS; Brierley JD; Ladenson PW; Ain KB; Fein HG; Haugen BR; Magner J; Skarulis MC; Steward DL; Xing M; Maxon HR; Sherman SI
J Clin Endocrinol Metab; 2015 Sep; 100(9):3270-9. PubMed ID: 26171797
[TBL] [Abstract][Full Text] [Related]
16. The effect of lithium on the progression-free and overall survival in patients with metastatic differentiated thyroid cancer undergoing radioactive iodine therapy.
Luo H; Tobey A; Auh S; Cochran C; Zemskova M; Reynolds J; Lima C; Burman K; Wartofsky L; Skarulis M; Kebebew E; Klubo-Gwiezdzinska J
Clin Endocrinol (Oxf); 2018 Oct; 89(4):481-488. PubMed ID: 29972703
[TBL] [Abstract][Full Text] [Related]
17. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma -- surgery or conventional therapy?
Zettinig G; Fueger BJ; Passler C; Kaserer K; Pirich C; Dudczak R; Niederle B
Clin Endocrinol (Oxf); 2002 Mar; 56(3):377-82. PubMed ID: 11940050
[TBL] [Abstract][Full Text] [Related]
19. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
20. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
